Stage (next event)
Phase 3 (Data)
Catalyst Info & Data Links
TITLE: EPIDIOLEX® (cannabidiol) for Rett syndrome - Phase 3 Data
ClinicalTrials.gov (NCT03848832): Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome (ARCH)
ClinicalTrials.gov (NCT04252586): An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome (ARCH)
WHAT IS THE CATALYST EVENT?
Phase 3 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
List last quarter's sales e.g. $137.1 million Q3/2020
2020 Revenue guidance: NOT PROVIDED by company
MECHANISM OF ACTION
The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post